Anton Pear 其旗舰产品 Lites i zer DIF 500 激光粒度仪 在药企研发设备采购中脱颖而出， Lites i zer DIF 500 激 光 粒 度 仪 提 供 粒度 从 10 nm 到 3.5 mm 的先进测量方式。这款激光衍射粒度分析仪配备了强大的 10 mW 和 25 mW 激光器，以及市场上最宽的检测衍射角范 围，即 0.01°-170°。并且，Kal l iope 软件简化了粒度测量，只需三次点击即可开始测量。 导读： 粒度仪作为新能源电池材料研发和医药质量控制的核心设备，现将上周（6.23-6.29）粒度仪中标信息进行盘点。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 粒度仪是新能源电池材料研发和医药质量控制的核心设备，现将上周（6.23-6.29）采购中标信息进行盘点 。 经平台搜索，上周共收录三条 粒度仪设备中标信息，涉及医药研发、新能源材料等领域。 其 中 ， 安 东 帕 Lites i zer DIF 激 光 粒 度 仪 以 55.9 万 元 高 价 中 标 某 知 名 药 企 研 发 中 心 ...

Core Viewpoint - The "9+5" industry is the main support for the high-quality economic development of Zhangzhou, with a focus on new industrialization and the cultivation of strategic emerging industries [1][28]. Economic Overview - Zhangzhou's GDP is projected to exceed 600 billion yuan, reaching 606.37 billion yuan in 2024, with a year-on-year growth of 6.1% [3]. - The primary industry added value is 61.50 billion yuan (3.7% growth), the secondary industry is 272.82 billion yuan (7.2% growth), and the tertiary industry is 272.05 billion yuan (5.4% growth) [3]. - Per capita GDP is 119,612 yuan, reflecting a 6.0% increase [3]. Industrial Structure - Zhangzhou is focusing on the "9+5" industry clusters, which include nine trillion-yuan industries such as food processing and petrochemicals, and five industries exceeding 500 billion yuan, including electronic information and digital services [11][13]. - The industrial added value of the nine major industries is expected to grow by 7.5% in 2024, with a growth of 8.8% in the first quarter of 2025 [28][17]. Investment and Infrastructure - In 2024, Zhangzhou added 1,987 fixed asset investment projects with a total investment of 224.54 billion yuan, marking an 8.5% year-on-year growth [7]. - Investment in the primary industry grew by 53.7%, while the secondary industry saw a 21.7% increase, with industrial investment specifically rising by 21.8% [7]. Foreign Trade - Zhangzhou's total import and export volume reached 127.68 billion yuan in 2024, a 4.9% increase from the previous year, with exports at 88.46 billion yuan (3.2% growth) and imports at 39.22 billion yuan (8.9% growth) [9]. - The actual use of foreign capital increased by 100.4% in 2024 [9]. Key Enterprises - As of the end of 2024, Zhangzhou has six A-share listed companies, including Pianzaihuang, Longxi Co., Zhangzhou Development, Aonong Bio, Wancheng Group, and Tailong Co. [23]. - The city has 949 enterprises with an output value exceeding 100 million yuan, with a 12.9% increase in added value [25]. Policy Support - Zhangzhou has implemented the "Thousand Billion Industry Cultivation Action Plan" to support the development of the "9+5" industry clusters, aiming for a scale industrial output value to exceed one trillion yuan by 2025 [13][28]. - The government is focusing on enhancing service levels and optimizing the business environment to support project construction and enterprise development [28].

Group 1 - The 9th China Time-honored Brand (Shandong) Expo is a significant national event organized by the Ministry of Commerce, showcasing over 600 time-honored enterprises from 26 provinces, with a focus on exploring new paths for these brands to expand globally [1] - The theme of the expo is "National Goods Trend, Everlasting Innovation," highlighting the deep heritage and innovative vitality of traditional brands, with Pizhou Huang (片仔癀) representing the traditional Chinese medicine sector [1] - Pizhou Huang's participation in the expo emphasizes its commitment to showcasing its full range of health products and engaging with attendees to demonstrate the charm of traditional Chinese craftsmanship [1] Group 2 - The 2025 China Time-honored Brand Traditional Chinese Medicine Development Conference focuses on building a development system that integrates cultural inheritance, technological empowerment, and collective synergy [2] - The conference introduced the first batch of the "Qihuang Twelve Palaces" list for promoting traditional Chinese medicine education, and signed a joint initiative for the integration of commerce, culture, and tourism [2] - Pizhou Huang was selected as one of the first enterprises in the "Qihuang Twelve Palaces," collaborating with other renowned brands to develop educational bases and museums, addressing key issues in the collective development of time-honored brands [2] Group 3 - Pizhou Huang, as a representative of time-honored brands, is achieving breakthroughs through innovation while preserving the roots of traditional Chinese medicine and leveraging technology to revitalize traditional wisdom in new consumer scenarios [3] - The company aims to establish a benchmark educational system in the industry by integrating top resources, enhancing the international dissemination of Chinese medicine culture, and showcasing Eastern wisdom to the world [3] - This initiative is expected to significantly enhance the core discourse power and influence of traditional Chinese medicine within the global health governance system [3]

Core Viewpoint - The announcement indicates a change in the controlling shareholder and actual controller of the company due to the transfer of state-owned shares from Jiulongjiang Group to Zhanglong Group, which is aimed at optimizing the structure of state-owned assets and enhancing the efficiency of state capital allocation [1][3]. Group 1: Shareholder Changes - Jiulongjiang Group will transfer 2,000,000 shares, representing 0.33% of the total share capital, to Zhanglong Group without compensation [3][4]. - After the transfer, Jiulongjiang Group will hold 307,522,643 shares, accounting for 50.97% of the total share capital [2][4]. - The transfer does not trigger mandatory tender offer obligations as it is a non-compensatory transfer [4][5]. Group 2: Shareholder Information - Jiulongjiang Group has a registered capital of 400 million RMB and is involved in various business activities including hazardous chemicals, oil wholesale, and construction [5]. - Zhanglong Group has a registered capital of 382.85 million RMB and engages in investment activities, agricultural services, and sales of various products [5][6]. Group 3: Compliance and Future Actions - Jiulongjiang Group has committed not to reduce its holdings in Zhanglong Group for 36 months following the completion of the share transfer [2][3]. - The company will fulfill its information disclosure obligations based on any future changes in shareholder holdings [7][8].

证券代码：600436 证券简称：片仔癀 公告编号：2025-019 漳州片仔癀药业股份有限公司关于国有股份无偿划转暨持 近日，公司收到控股股东九龙江集团《关于公司股份变动的告知 函》，现将本次权益变动情况公告如下： 1 本次权益变动系无偿划转，不触及要约收购。 本次权益变动不会使漳州片仔癀药业股份有限公司（以下简称"公 司"）控股股东及实际控制人发生变化。 本次权益变动后，信息披露义务人漳州市九龙江集团有限公司（以 下简称"九龙江集团"）仍持有公司 307,522,643 股，占公司总股 本 50.97%。 本次权益变动后，福建漳龙集团有限公司（以下简称"漳龙集团"） 承诺自股份过户登记完成之日起 36 个月内，不以任何方式主动减 持本次无偿划转中所取得的股份。 一、 本次国有股份无偿划转的基本情况 近日，九龙江集团收到漳州市国资委《关于划转九龙江集团持有 的公司部分股份的通知》，为进一步优化调整国有资产结构布局，提 升国有资本配置效率，整合推动市属国有企业高质量发展，九龙江集 团拟将其持有的公司 2,000,000 股（占公司总股本 0.33%）无偿划转 至漳龙集团。 2025 年 6 月 20 日，九龙 ...

金十数据6月23日讯，片仔癀公告称，九龙江集团拟将其持有的公司200万股无偿划转至漳龙集团。划转 后，九龙江集团仍持有公司307,522,643股，占总股本50.97%，漳龙集团持股增至1.17%。 片仔癀：九龙江集团拟将部分股份无偿划转至漳龙集团 ...

| 000538 | 云南白药 | -0.02 | 0.29 | -464.02 | | --- | --- | --- | --- | --- | | 603195 | 公牛集团 | -3.31 | 0.27 | -294.27 | | 000599 | 青岛双星 | 1.20 | 1.94 | -269.88 | | 603031 | 安孚科技 | 0.68 | 0.92 | -259.74 | | 603043 | 广州酒家 | -0.84 | 0.32 | -234.96 | | 002820 | 桂发祥 | 2.19 | 2.89 | -64.03 | | 600305 | 恒顺醋业 | 0.26 | 0.46 | 1.38 | | 603156 | 养元饮品 | -1.67 | 0.17 | 8.65 | | 001328 | 登康口腔 | 2.08 | 5.37 | 12.71 | | 002568 | 百润股份 | 0.53 | 1.34 | 13.18 | | 300999 | 金龙鱼 | 0.94 | 0.78 | 37.38 | | 000100 | TCL科技 | -0.46 | 0. ...

Core Viewpoint - The company aims to build itself into a world-class, top-tier pharmaceutical health industry group through continuous efforts in drug research and development, pharmaceutical commerce, daily chemical beauty, health food, and investment mergers and acquisitions, guided by the development philosophy of "Upholding Integrity and Innovation, Steady Progress for the Long Term" [2][11]. Company Strategy and Development - The 2024 annual shareholder meeting successfully completed voting on seven proposals, including the annual report, and highlighted the company's commitment to innovation and steady development [3][10]. - The company has prioritized "increasing technological innovation" in its future work plan for 2025, emphasizing the importance of innovation for sustainable development in the pharmaceutical industry [4][11]. Research and Development Achievements - The company has conducted 11 clinical studies and 23 pharmacological and toxicological studies for its core product, Pizhouhuang, and published 23 related research papers, showcasing significant results in the secondary development of traditional Chinese medicine [5][6]. - Pizhouhuang has been included in the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024)" by the Chinese Association of Traditional Chinese Medicine, indicating its recognition as a recommended drug for this condition [6]. Product Pipeline and Future Plans - The company has developed a pipeline of 18 projects covering traditional Chinese medicine and chemical drugs, targeting urgent clinical needs such as non-alcoholic fatty liver disease and chronic obstructive pulmonary disease, with plans to initiate 2 new drug projects and 3 to 5 new clinical studies in 2025 [7][11]. - The company is committed to increasing R&D investment to create "blockbuster" products in both traditional Chinese and chemical medicine, aiming to generate greater value for shareholders [7][11]. Shareholder Engagement - The shareholder meeting featured active participation from shareholders, with discussions on core product pricing, cash dividends, marketing strategies, and brand reputation, demonstrating transparency and engagement from the company's management [3][8][9]. - The company has implemented strategies to stabilize product pricing and enhance sales performance through optimized channels and partnerships with major online platforms [9]. Conclusion - The company is positioned as a leader in the traditional Chinese medicine industry, focusing on both core product enhancement and innovative drug development to explore new growth avenues while maintaining its heritage [11].

Core Points - The company held a shareholders' meeting on June 20, 2025, at the Zhangzhou Xiangjiang Hotel [2] - All resolutions proposed during the meeting were approved with significant majority votes [1][3] Voting Results - The voting results showed that the majority of A-shareholders voted in favor of the resolutions, with approval rates ranging from 99.7391% to 99.8057% [1][3] - Specific voting numbers included 352,396,154 votes (99.7845% approval) for one resolution and 352,471,154 votes (99.8057% approval) for another [1] Legal Compliance - The meeting and voting procedures complied with the Company Law and the company's articles of association, ensuring the legitimacy of the proceedings [1][3] - The presence of legal representatives confirmed that the meeting adhered to all relevant legal and regulatory requirements [3]

证券代码：600436 证券简称：片仔癀 公告编号：2025-018 漳州片仔癀药业股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 2,023 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 353,157,040 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | 58.5358 | | 总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 表决方式符合《公司法》及《漳州片仔癀药业股份有限公司章程》（以下简 称"《公司章程》"）的规定，公司董事长林志辉先生主持本次会议。大会采用网 络投票和现场投票相结合的方式进行表决。会议的召开和表决程序符合《公司法》 (一) 股东会召开的时间：2025 年 6 月 20 日 (二) 股东会召开的地点：漳州市芗城区漳州芗江酒店二楼（芝 ...